New analysis backs benefit-risk profile of Merck’s Mavenclad

27th October 2017 Uncategorised 0

Merck has released new data showing a positive benefit-risk profile for its multiple sclerosis drug Mavenclad.

More: New analysis backs benefit-risk profile of Merck’s Mavenclad
Source: News